Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jun 23:27:30418.
doi: 10.3402/mehd.v27.30418. eCollection 2016.

Double-blind controlled randomised study of lactulose and lignin hydrolysed combination in complex therapy of atopic dermatitis

Yuri N Perlamutrov  1 , Kira B Olhovskaya  1 , Svetlana A Zakirova  2
Affiliations

Double-blind controlled randomised study of lactulose and lignin hydrolysed combination in complex therapy of atopic dermatitis

Yuri N Perlamutrov et al. Microb Ecol Health Dis. .

Abstract

Background: Atopic dermatitis (AD) is an immune mediated disease with complex pathogenesis characterised by persistency, frequent exacerbations, and inefficacy of existing therapies. Damaged or weakened intestinal microbiocenosis is considered as an important aetiological factor of AD. The aim of this study was to evaluate the efficacy and safety of medical preparation Lactofiltrum (lactulose and sorbent (lignin hydrolysed)) in comparison with placebo in complex with standard therapy of AD.

Methods: Double-blind, placebo controlled, randomised comparative study of effectiveness and safety of 400 mg lactulose and 120 mg lignin hydrolysed combination as a part of standard combined AD treatment, conducted in parallel groups of patients aged 18-60.

Results: Comparison of clinical efficacy of Lactofiltrum in combination with the standard treatment has been demonstrated by measuring the following parameters: administration of Lactofiltrum results in 1) distinct clinical improvement in 56.75% of patients, 2) decrease of the mean values of scoring atopic dermatitis (SCORAD) index in 71.94% of patients, 3) elimination of itching in 50% of patients, and 4) life quality improvement for 76.41%. In the placebo group, 1) distinct clinical improvement was observed in 20% of patients, 2) decrease in SCORAD index values observed by 56.98%, 3) itching relief in 15.56%, and 4) life quality improvement by 36.38%.

Conclusions: Clinical improvement and persistent termination of clinical symptoms provide evidence of effectiveness in use of Lactofiltrum combined with the standard treatment of AD.

Keywords: Lactofiltrum; allergic disease; atopic dermatitis; lactulose; lignin hydrolysed.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Skin lesions disappearance as a result of treatment with Lactofiltrum (Group 1) compared to the control (Group 2) on 21 day of treatment.
Fig. 2
Fig. 2
Efficacy of AD treatment with Lactofiltrum (Group 1) compared to the control (Group 2), in %.
See this image and copyright information in PMC

References

    1. Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis. Acta Derm Venereo (Stockh.) 1980;92(Suppl):44–7.
    1. Leung D. Role of IgE in atopic dermatitis. Curr Opin Immunol. 1993;5:956–62. - PubMed
    1. Herz U, Bunikowski R, Renz H. Role of T cells in atopic dermatitis. New aspects on the dynamics of cytokine production and the contribution of bacterial superantigens. Int Arch Allergy Immunol. 1998;115:179–90. - PubMed
    1. Watanabe S, Narisawa Y, Arase S, Okamatsu H, Ikenaga T, Tajiri Y, et al. Differences in fecal microflora between patients with atopic dermatitis and healthy control subjects. J Allergy Clin Immunol. 2005;111:587–91. - PubMed
    1. Kokkonen J, Similä S, Herva R. Gastrointestinal findings in atopic children. Eur J Pediatr. 1980;134:249–54. - PubMed

LinkOut - more resources